Sutro Biopharma (STRO) Restructuring Costs (2025)

Name: Sutro Biopharma (STRO) Restructuring Costs (2025) | Business Quant
Creator: Business Quant

Sutro Biopharma recorded quarterly Restructuring Costs of $1.6 million in Q4 2025, down 78.39% quarter-over-quarter from $7.3 million in Q3 2025.

Sutro Biopharma's Restructuring Costs history runs 1 years deep, the most recent figure standing at $1.6 million for Q4 2025.

In Q4 2025, Restructuring Costs changed N/A year-over-year to $1.6 million; the TTM figure through Dec 2025 stood at $26.1 million (changed N/A YoY), while the FY2025 annual figure was $26.1 million, changed N/A from the prior year.
Restructuring Costs came in at $1.6 million for Q4 2025 at Sutro Biopharma, down from $7.3 million in the prior quarter.
In the past five years, Restructuring Costs ranged from a high of $13.0 million in Q2 2025 to a low of $1.6 million in Q4 2025.

Peer Comparison

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Quantum Biopharma	961,148.99 Bn	961,148.98 Bn	-
2	Alterity Therapeutics	744,933.29 Bn	744,933.26 Bn	-
3	Legend Biotech	2,540.00 Bn	2,539.71 Bn	242.10 Mn
4	Nanobiotix	2,199.85 Bn	2,199.78 Bn	-
5	Akari Therapeutics	1,635.88 Bn	1,635.88 Bn	-
6	Vertex Pharmaceuticals	111.32 Bn	104.07 Bn	2.59 Bn
7	Evaxion A	62.56 Bn	62.54 Bn	-
8	Regeneron Pharmaceuticals	62.55 Bn	53.79 Bn	3.31 Bn
9	Alnylam Pharmaceuticals	39.57 Bn	36.56 Bn	959.66 Mn
10	Sutro Biopharma	242.87 Mn	242.87 Mn	-

Download Data 🔒